• Users Online: 86
  • Print this page
  • Email this page
CASE REPORT
Year : 2022  |  Volume : 19  |  Issue : 1  |  Page : 36-38

Newer drug for the resistant bug: A case report of spondylodiscitis with Klebsiella pneumoniae producing carbapenemase managed successfully with ceftazidime-avibactam


1 Department of Microbiology, Central Laboratory, People Tree Hospitals, Bengaluru, Karnataka, India
2 Department of Infectious Diseases, Manipal Hospitals, Bengaluru, Karnataka, India
3 Department of Spine Surgery and Orthopedics, People Tree Hospitals, Bengaluru, Karnataka, India

Correspondence Address:
Sushma Krishna
Department of Microbiology, Central Laboratory, People Tree Hospitals, Yeshwanthpur, Bengaluru - 560 022, Karnataka
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/joasis.joasis_2_22

Rights and Permissions

Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae are multidrug resistant organisms that have been increasingly recognized to cause infections with high mortality. The therapeutic options available for treating such infections stand severely compromised. The use of ceftazidime-avibactam in bacteremia and other infections by these organisms has been reported. We report a case of spondylodiscitis caused by KPC-KP diagnosed by pan-bacterial DNA screen and successfully treated with this relatively newer antibiotic. This report highlights the importance of the utility of molecular diagnostic tests in routine practice.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed108    
    Printed0    
    Emailed0    
    PDF Downloaded4    
    Comments [Add]    

Recommend this journal